G1 Therapeutics Shares Conclude Trading Following Acquisition

The publicly traded journey of G1 Therapeutics has reached its conclusion. The biotechnology firm ceased trading on the NASDAQ effective September 18, 2024, following its acquisition by Pharmacosmos A/S. This corporate action finalizes the investment timeline for shareholders.

Pharmacosmos Therapeutics, a Danish pharmaceutical company, secured all outstanding G1 Therapeutics shares in a transaction valued at approximately $405 million. The acquisition price was set at $7.15 per share, representing a significant premium compared to pre-announcement trading levels.

The tender offer succeeded with approximately 75% of shares tendered. Subsequent to the acquisition, G1 Therapeutics merged with a subsidiary of Pharmacosmos, resulting in its delisting from the public market. The company’s trading symbol, GTHX, has Read more...